Thyroid Hormone Transport into Cellular Tissue
Kent Holtorf


Thyroid hormone transport
Membrane transport
Reverse T3 (RT3)
Free T3/reverse T3 ratio
Basal body temperature


New research is demonstrating that thyroid hormone transport across cellular membranes plays an important role in intracellular triiodothyronine (T3) levels of peripheral and pituitary tissues and is proving to have considerable clinical significance. Reduced T4 and T3 transport into the cells in peripheral tissues is seen with a wide range of common conditions, including insulin resistance, diabetes, depression, bipolar disorder, hyperlipidemia, chronic fatigue syndrome, fibromyalgia, neurodegenerative diseases, migraines, stress, anxiety, chronic dieting and aging, while the intracellular T3 level in the pituitary often remains unaffected. The pituitary has different transporters than every other tissue in the body. The thyroid transporters in the body are very energy dependent and are affected by numerous conditions, including low energy states, toxins and mitochondrial dysfunction, while the pituitary remains unaffected. Because the pituitary remains largely unaffected and is able to maintain intracellular T3 levels while the rest of the body suffers from significantly reduced intracellular T3 levels, there is no elevation in thyroid-stimulating hormone (TSH) despite the presence of wide-spread tissue hypothyroidism, making the TSH and other standard blood tests a poor marker to determine the presence or absence of hypothyroidism. Because the T4 transporter is more energy dependent than the transporter for T3, it is also not surprising that T4 preparations are generally ineffective in the presence of such conditions, while T3 replacement is shown to be beneficial. Thus, if a patient with a normal TSH presents with signs or symptoms consistent with hypothyroidism, which may include low basal body temperature, fatigue, weight gain, depression, cold extremities, muscle aches, headaches, decreased libido, weakness, cold intolerance, water retention, slow reflex relaxation phase or PMS, a combination of both clinical and laboratory assessment, which may include a T3/reverse T3 ratio and the level of sex hormone binding globulin (SHBG), should be used to determine the likely overall thyroid status and if a therapeutic trail of straight T3 or a T4/T3 combination is indicated and not based solely on standard thyroid function tests.



Everts ME, De Jong M, Lim CF, et al. Different regulation of thyroid hormone transport in liver and pituitary: its possible role in the maintenance of low T3 production during nonthyroidal illness and fasting in man. Thyroid. 1996; 6(4):359–68.
Peeters RP, Geyten SV, Wouters PJ, et al. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab. 2005; 12:6498–507.
Lim C-F, Docter R, Krenning EP, et al. Transport of thyroxine into cultured hepatocytes: effects of mild nonthyroidal illness and calorie restriction in obese subjects. Clin Endocrinol (Oxf). 1994; 40:79–85.
Sarne DH, Refetoff S. Measurement of thyroxine uptake from serum by cultured human hepatocytes as an index of thyroid status: reduced thyroxine uptake from serum of patients with nonthyroidal illness. J Clin Endocrinol Metab. 1985; 61:1046–52.
Hennemann G, Docter R, Friesema EC, et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocrine Rev. 2001; 22(4):451–76.
Holm AC, Jacquemin C. Membrane transport of L-triiodothyronine by human red cell ghosts. Biochem Biophys Res Commun. 1979; 89:1006–17.
Docter R, Krenning EP, Bos G, Fekkes DSF, Hennemann G. Evidence that the uptake of triiodo-L-thyronine by human erythrocytes is carrier-mediated but not energy-dependent. Biochem J. 1982; 208:27–34.
Holm AC, Kagedal B. Kinetics of triiodothyronine uptake by erythrocytes in hyperthyroidism, hypothyroidism, and thyroid hormone resistance. J Clin Endocrinol Metab. 1989; 69:364–8.
Osty J, Valensi P, Samson M, Francon J, Blondeau JP. Transport of thyroid hormones by human erythrocytes: kinetic characterization in adults and newborns. J Clin Endocrinol Metab. 1990; 71:1589–95.
Moreau X, Azorin J-M, Maurel M, Jeanningros R. Increase in red blood cell triiodothyronine uptake in untreated unipolar major depressed patients compared to healthy controls. Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22:293–310.
Osty J, Jego L, Francon J, Blondeau JP. Characterization of triiodothyronine transport and accumulation in rat erythrocytes. Endocrinology. 1988; 123:2303–11.
Osty J, Zhou Y, Chantoux F, Francon J, Blondeau JP. The triiodothyronine carrier of rat erythrocytes: asymmetry and mechanism of transinhibition. Biochim Biophys Acta. 1990; 1051:46–51.
Moreau X, Lejeune PJ, Jeanningros R. Kinetics of red blood cell T3 uptake in hypothyroidism with or without hormonal replacement, in the rat. J Endocrinol Invest. 1999; 22:257–61.
McLeese JM, Eales JG. 3,5,3-Triiodo-L-thyronine and L-thyroxine uptake into red blood cells of rainbow trout (Oncorhynchus mykiss). Gen Comp Endocrinol. 1996; 102:47–55.
McLeese JM, Eales JG. Characteristics of the uptake of 3,5,3-triiodo-L-thyronine and L-thyroxine into red blood cells of rainbow trout (Oncorhynchus mykiss). Gen Comp Endocrinol. 1996; 103:200–8.
Everts ME, Docter R, van Buuren JC, et al. Evidence of carrier-mediated uptake of triiodothyronine in cultured anterior pituitary cells of euthyroid rats. Endocrinology. 1993; 132:1278–85.
Everts ME, Docter R, Moerings EP, van Koetsveld PM, Visser TJ, et al. Uptake of thyroxine in cultured anterior pituitary cells of euthyroid rats.Endocrinology. 1994; 134:2490–7.
Yan Z, Hinkle PM. Saturable, stereospecific transport of 3,5,3-triiodo-L-thyronine and L-thyroxine into GH4C1 pituitary cells. J Biol Chem. 1993; 268:20179–84.
Goncalves E, Lakshmanan M, Pontecorvi A, Robbins J. Thyroid hormone transport in a human glioma cell line. Mol Cell Endocrinol. 1990; 69:157–65.
Francon J, Chantoux F, Blondeau JP. Carrier-mediated transport of thyroid hormones into rat glial cells in primary culture. J Neurochem. 1989; 53:1456–63.
Beslin A, Chantoux F, Blondeau JP, Francon J. Relationship between the thyroid hormone transport system and the Na-H exchanger in cultured rat brain astrocytes. Endocrinology. 1995; 136:5385–90.
Chantoux F, Blondeau JP, Francon J. Characterization of the thyroid hormone transport system of cerebrocortical rat neurons in primary culture.J Neurochem. 1995; 65:2549–54.
Kastellakis A, Valcana T. Characterization of thyroid hormone transport in synaptosomes from rat brain. Mol Cell Endocrinol. 1989; 67:231–41.
Lakshmanan M, Goncalves E, Lessly G, et al. The transport of thyroxine into mouse neuroblastoma cells, NB41A3: the effect of L-system amino acids. Endocrinology. 1990; 126:3245–50.
Pontecorvi A, Lakshmanan M, Robbins J. Intracellular transport of 3,5,3-triiodo-L-thyronine in rat skeletal myoblasts. Endocrinology. 1987; 121:2145–52.
Everts ME, Verhoeven FA, Bezstarosti K, et al. Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology. 1996; 137:4235–42.
Zonefrati R, Rotella CM, Toccafondi RS, Arcangeli P. Thyroid hormone receptors in human cultured fibroblasts: evidence for cellular T4 transport and nuclear binding. Horm Metab Res. 1983; 15:151–4.
Docter R, Krenning EP, Bernard HF, Hennemann G. Active transport of iodothyronines into human cultured fibroblasts. J Clin Endocrinol Metab. 1987; 65:624–8.
Cheng SY. Characterization of binding of uptake of 3,3,5-triiodo-L-thyronine in cultured mouse fibroblasts. Endocrinology. 1983; 112:1754–62.
Mitchell AM, Manley SW, Mortimer RH. Uptake of L-triiodothyronine by human cultured trophoblast cells. J Endocrinol. 1992; 133:483–6.
Mitchell AM, Manley SW, Mortimer RH. Membrane transport of thyroid hormone in the human choriocarcinoma cell line JAR. Mol Cell Endocrinol. 1992; 87:139–45.
Mitchell AM, Manley SW, Rowan KA, Mortimer RH. Uptake of reverse T3 in the human choriocarcinoma cell line JAR. Placenta. 1999; 20:65–70.
Bernus I, Mitchell AM, Manley SW, Mortimer RH. Uptake of L-triiodothyronine sulfate by human choriocarcinoma cell line JAR. Placenta. 1999; 20(2–3):161–5.
Mitchell AM, Manley SW, Payne EJ, Mortimer RH. Uptake of thyroxine in the human choriocarcinoma cell line JAR. J Endocrinol. 1995; 146:233–8.
Landeta LC, Gonzales-Padrones T, Rodriguez-Fernandez C. Uptake of thyroid hormones (L-T3 and L-T4) by isolated rat adipocytes. Biochem Biophys Res Commun. 1987; 145:105–10.
Kostrouch Z, Felt V, Raska J, Nedvidkova J, Holeckova E. Binding of (125I) triiodothyronine to human peripheral leukocytes and its internalization. Experientia. 1987; 43:1117–8.
Kostrouch Z, Raka I, Felt V, Nedvidkova J, Holeckova E. Internalization of triiodothyronine-bovine serum albumin-colloidal gold complexes in human peripheral leukocytes. Experientia. 1987; 43:1119–20.
Centanni M, Mancini G, Andreoli M. Carrier-mediated [125I]-T3 uptake by mouse thymocytes. Endocrinology. 1989; 124:2443–8.
Centanni M, Sapone A, Taglienti A, Andreoli M. Effect of extracellular sodium on thyroid hormone uptake by mouse thymocytes. Endocrinology. 1991; 129:2175–9.
de Jong M, Docter R, Bernard HF, et al. T4 uptake into the perfused rat liver and liver T4 uptake in humans are inhibited by fructose. Am J Physiol. 1994; 266:E768–75.
Hennenmann G, Everts ME, de Jong M, et al. The significance of plasma membrane transport in the bioavailability of thyroid hormone. Clin Endocrinol (Oxf). 1998; 48:1–8.
Vos RA, de Jong M, Bernard BF, et al. Impaired thyroxine and 3,5,3′-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness. J Clin Endocrinol Metab. 1995; 80:2364–70.
Hennemann G, Krenning EP. The kinetics of thyroid hormone transporters and their role in non-thyroidal illness and starvation. Best Pract Res Clin Endocrinol Metab. 2007; 21(2):323–38.
Hennemann G, Vos RA, de Jong M, et al. Decreased peripheral 3,5,3′-triiodothyronine (T3) production from thyroxine (T4): a syndrome of impaired thyroid hormone activation due to transport inhibition of T4- into T3-producing tissues. J Clin Endocrinol Metabol. 1993; 77(5):1431–5.
Stump CS, Short KR, Bigelow ML, et al. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA. 2003; 100(13):7996–8001.
Krenning EP, Docter R, Bernard HF, et al. The essential role of albumin in the active transport of thyroid hormones into primary cultured rat hepatocytes. FEBS Lett. 1979; 107(1):227–30.
Krenning EP, Docter R, Bernard HF, et al. Regulation of the active transport of 3,3′,5-triiodothyronine (T3) into primary cultured rat hepatocytes by ATP. FEBS Lett. 1980; 119(2):279–82.
van der Heyden JT, Docter R, van Toor H, et al. Effects of caloric deprivation on thyroid hormone tissue uptake and generation of low-T3 syndrome. Am J Physiol Endocrinol Metab. 1986; 251(2):E156–63.
Wassen FWJS, Moerings EPCM, van Toor H, et al. Thyroid hormone uptake in cultured rat anterior pituitary cells: effects of energy status and bilirubin. J Endocrinol. 2000; 165:599–606.
Jenning AS, Ferguson DC, Utiger RD. Regulation of the conversion of thyroxine to triiodothyronine in the perfused rat liver. J Clin Invest. 1979; 64:1614–23.
Krenning E, Docter R, Bernard B, Visser T, Hennemann G. Characteristics of active transport of thyroid hormone into rat hepatocytes. Biochim Biophys Acta. 1981; 676:314–20.
Riley WW, Eales JG. Characterization of 3,5,3-triiodo-L-thyronine transport into hepatocytes isolated from juvenile rainbow trout (Oncorhynchus mykiss), and comparison with L-thyroxine transport. Gen Comp Endocrinol. 1994; 95:301–9.
Spencer CA, Lum SMC, Wilber JF, et al. Dynamics of serum thyrotropin and thyroid hormone changes in fasting. J Clin Endocrin Metab. 1983; 56(5):883–8.
St Germain DL, Galton VA. Comparative study of pituitary-thyroid hormone economy in fasting and hypothyroid rats. J Clin Invest. 1985; 75(2):679–88.
Arem R, Wiener GJ, Kaplan SG, Kim HS, et al. Reduced tissue thyroid hormone levels in fatal illness. Metabolism. 1993; 42(9):1102–8.
Lim C-F, Bernard BF, De Jong M, et al. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab. 1993; 76:318–24.
Lim C-F, Docter R, Visser TJ, Krenning EP, Bernard B, et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of non-uremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metab. 1993; 76:1165–72.
Lim VS, Passo C, Murata Y, Ferrari E, et al. Reduced triiodothyronine content in liver but not pituitary of the uremic rat model: demonstration of changes compatible with thyroid hormone deficiency in liver only. Endocrinology. 1984; 114:280–6.
Everts ME, Lim C-F, Moerings EPCM, Docter R, et al. Effects of a furan fatty acid and indoxyl sulfate on thyroid hormone uptake in cultured anterior pituitary cells. Am J Physiol. 1995; 268:E974–9.
Doyle D. Benzodiazepines inhibit temperature dependent L-[125I] triiodothyronine accumulation into human liver, human neuroblast, and rat pituitary cell lines. Endocrinology. 1992; 130:1211–6.
Krenning EP, Docter R, Bernard HF, et al. Decreased transport of thyroxine (T4), 3,3′,5-triiodothyronine (T3) and 3,3′,5′-triiodothyronine (rT3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs. FEBS Lett. 1982; 140:229–33.
Kaptein EM, Robinson WJ, et al. Peripheral serum thyroxine, triiodothyronine, and reverse triiodothyronine in the low thyroxine state of acute nonthyroidal illness. A noncompartmental analysis. J Clin Invest. 1982; 69:526–35.
Kaptein EM, Kaptein JS, Chang EI, et al. Thyroxine transfer and distribution in critical nonthyroidal illness, chronic renal failure, and chronic ethanol abuse. J Clin Endocrinol Metab. 1987; 65:606–16.
Everts ME, Visser TJ, Moerings EM, Docter R, et al. Uptake of triiodothyroacetic acid and its effect on thyrotropin secretion in cultered anterior pituitary cells. Endocrinology. 1994; 135(6):2700–7.
De Jong M, Docter R, van der Hoek HJ, Vos RA. Transport of 3,5,3′-triiodothyronine into the perfused rat liver and subsequent metabolism are inhibited by fasting. Endocrinology. 1992; 131(1):463–70.
Hennemann G, Krenning EP, Bernard B, Huvers F, et al. Regulation of Influx and efflux of thyroid hormones in rat hepatocytes: possible physiologic significance of plasma membrane in the regulation of thyroid hormone activity. Horm Metab Res Suppl. 1984; 14:1–6.
Petersen KF, Dufour S, Shulman GI. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of Type 2 diabetic parents. PLoS Med. 2005; 2(9):e233.
Szendroedi J, Schmid AI, Meyerspeer M, et al. Impaired mitochondrial function and insulin resistance of skeletal muscle in mitochondrial diabetes. Diabetes Care. 2009; 32(4):677–9.
Abdul-Ghani MA, Jani R, Chavez A, et al. Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants. Diabetologia. 2009; 52(4):574–82.
Verga SB, Donatelli M, Orio L, et al. A low reported energy intake is associated with metabolic syndrome. J Endocrinol Invest. 2009; 32:538–41.
Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol. 2007; 83(1):84–92.
Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005; 39(1):359–407.
Fosslien E. Mitochondrial medicine – Molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci. 2001; 31(1):25–67.
West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000; 17(3):171–80.
Brehm A, Krssak M, Schmid AI, et al. increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes. 2006; 55:136–40.
DeMarco NM, Beitz DC, Whitehurst GB. Effect of fasting on free fatty acid, glycerol and cholesterol concentrations in blood plasma and lipoprotein lipase activity in adipose tissue of cattle. J Anim Sci. 1981; 52:75–82.
Leibel RL, Jirsch J. Diminshed energy requirements in reduced-obese patients. Metabolism. 1984; 33(2):164–70.
Steen SN, Opplieger RA, Brownell KD. Metabolic effects of repeated weight and regain in adolescent wrestlers. J Am Med Assoc. 1988; 260:47–50.
Elliot DL, Goldberg L, Kuehl KD, Bennett WM. Sustained depression of the resting metabolic rate after massive weight loss. Am J Clin Nutr. 1989; 49:93–6.
Manore MM, Berry TE, Skinner JS, Carroll SS. Energy expenditure at rest and during exercise in nonobese female cyclical dieters and in nondieting control subjects. Am J Clin Nutr. 1991; 54:41–6.
Croxson MS, Ibbertson HK. Low serum triiodothyronine (T3) and hypothyroidism in anorexia nervosa. J Clin Endorinol Metab. 1977; 44:167–74.
Carlin K, Carlin S. Possible etiology for euthyroid sick syndrome. Med Hypotheses. 1993; 40:38–43.
Brownell KD, Greenwood MR, Stellar E, Shrager EE. The effects of repeated cycles of weight loss and regain in rats. Physiol Behav. 1986; 38(4):459–64.
Modica-Napolitano JS, Renshaw PF. Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder. Biol Psychiatry. 2004; 55(3):273–7.
Gardner A, Boles RG. Mitochondrial energy depletion in depression with somatization. Psychother Psychosom. 2008; 77:127–9.
Burroughs S, French D. Depression and anxiety: role of mitochondria. Curr Anaesth Crit Care. 2007; 18:34–41.
Einat H, Yuan P, Manji HK. Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res. 2005; 165(2):172–80.
Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry. 2005; 10(10):900–19.
Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases.Psychosomatics. 2006; 47(1):1–7.
Hutchin T, Cortopassi G. A mitochondrial DNA clone is associated with increased risk for Alzheimer’s disease. Proc Natl Acad Sci USA. 1995; 92:6892–5.
Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinson’s disease. Neuroscientist. 2002; 8(3):192–7.
Gomez C, Bandez MJ, Navarro A. Pesticides and impairment of mitochondrial function in relation with the Parkinsonian syndrome. Front Biosci. 2007; 12:1079–93.
Stavrovskaya IG, Kristal BS. The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radic Biol Med. 2005; 38(6):687–97.
Schapira AHV. Mitochondrial disease. Lancet. 2006; 368:70–82.
Richter C. Oxidative damage to mitochondrial DNA and its relationship to aging. Int J Biochem Cell Biol. 1995; 27(7):647–53.
Papa S. Mitochondrial oxidative phosphorylation changes in the life span. Molecular aspects and physiopathological implications. Biochim Biophys Acta. 1996;87–105.
Cortopassi G, Wang A. Mitochondria in organismal aging and degeneration. Biochim Biophys Acta. 1999; 1410:183–93.
Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc. 1972; 20:145–7.
Miquel J, Economos AC, Fleming J, Johnson JE. Mitochondrial role in cell aging. Exp Gerontol. 1980; 15:575–91.
Miquel J. An integrated theory of aging as the result of mitochondrial DNA mutation in differentiated cells. Arch Gerontol Geriatr. 1991; 12:99–117.
Miquel J. An update on the mitochondrial-DNA mutation hypothesis of cell aging. Mutat Res. 1992; 275:209–16.
Zs.-Nagy I. A membrane hypothesis of aging. J Theor Biol. 1978; 75:189–95.
Zs.-Nagy I. The role of membrane structure and function in cellular aging: a review. Mech Aging Dev. 1979; 9:37–246.
Savitha S, Sivarajan K, Haripriya D, et al. Efficacy of levo carnitine and alpha lipoic acid in ameliorating the decline in mitochondrial enzymes during aging. Clin Nutr. 2005; 24(5):794–800.
Skulachev VP, Longo VD. Aging as a mitochondria-mediated atavistic program: can aging be switched off? Ann NY Acad Sci. 2005; 1057:145–64.
Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res. 1992; 275(3–6):169–80.
Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA. 1993; 90(17):7915–22.
Fulle S, Mecocci P, Fano G, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med. 2000; 29(12):1252–9.
Buist R. Elevated xenobiotics, lactate and pyruvate in C.F.S. patients. J Orthomolec Med. 1989; 4(3):170–2.
Park JH, Niermann KJ, Olsen N. Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia. Curr Rheumatol Rep. 2000; 2(2):131–40.
Yunus MB, Kalyan-Raman UP, Kalyan-Raman K. Primary fibromyalgia syndrome and myofascial pain syndrome: clinical features and muscle pathology. Arch Phys Med Rehabil. 1988; 69(6):451–4.
Puddu P, Puddu GM, Galletti L, Cravero E, Muscari A. Mitochondrial dysfunction as an initiating event in atherogenesis: a plausible hypothesis.Cardiology. 2005; 103(3):137–41.
Chen L, Knowlton AA. Depressed mitochondrial fusion in heart failure. Circulation. 2007; 116:259.
Kaptein EM, Feinstein EI, Nicoloff JT, Massry SG. Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. J Clin Endocrinol Metab. 1983; 57:181–9.
Kaptein EM. Thyroid hormone metabolism and thyroid disease in chronic renal failure. Endocr Rev. 1996; 17:45–63.
Kaptein EM. Clinical relevance of thyroid hormone alterations in nonthyroidal illness. Thyroid Int. 1997; 4:22–5.
Kigoshi S, Akiyama M, Ito R. Close correlation between levels of cholesterol and free fatty acids in lymphoid cells. Cell Mol Life Sci. 1976; 32(10):1244–6.
Bochukova E, Schoenmakers N, Agostini M, et al. A mutation in the thyroid hormone receptor alpha gene. N Engl J Med. 2012; 366:243–9.
Meier C, Trittibach P, Guglielmetti M, Staub JJ, Muller B. Serum TSH in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey. Br Med J. 2003; 326:311–2.
Alevizaki M, Mantzou E, cimponeriu AT, et al. TSH may not be a good marker for adequate thyroid hormone replacement therapy. Wien Klin Wochenschr. 2005; 117/18:636–40.
Zulewski H, Muller B, Exer P, et al. Estimation of tissue hypothyrodisim by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab. 1997; 82(3):771–6.
van den Beld AW, Visser TJ, Feelders RA, et al. Thyroid hormone concentrations, disease, physical function and mortality in elderly men. J Clin Endocrinol Metab. 2005; 90(12):6403–9.
Singer PA, Cooper DS, Levy EG, et al. for the Standards of Care Committee, American Thyroid Association. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. J Am Med Assoc. 1995; 273:808–12.
Escobar-Morreale HF, Obregón MJ, Escobar del Rey F, et al. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest. 1995; 96(6):2828–38.
Escobar-Morreale HF, Obregón MJ, Escobar del Rey F. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology. 1996; 137:2490–502.
Fraser WD, Biggart EM, OReilly DJ, et al. Are biochemical tests of thyroid function of any value in monitoring patients receiving thyroxine replacement? Br Med J. 1986; 293:808–10.
Lecomte P, Lecureuil N, Lecureuil M, Salazar CO, Valat C. Age modulates effects of thyroid dysfunction on sex hormone binding globulin (SHBG) levels. Exp Clin Endocrinol. 1995; 103:339–42.
Sarne DH, Refetoff S, Rosenfield RL, Farriaux JP. Sex hormone-binding globulin in the diagnosis of peripheral tissue resistance to thyroid hormone: the valued of changes after short term triiodothyronine administration. J Clin Endocrinol Metab. 1988; 66(4):740–6.
Krotkiewski M, Holm G, Shono N. Small doses of triiodothyronine can change some risk factors associated with abdominal obesity. Int J Obes Relat Metab Disord. 1997; 21:922–9.
Birkeland KI, Hanssen KF, Torjesen PA, et al. Level of Sex Hormone-binding globulin is positively correlated with insulin sensitivity in men with Type 2 diabetes. J Clin Endocrinol Metab. 1993; 76:275–8.
Chen BH, Brennan K, Goto A. Sex hormone-binding globulin and risk of clinical diabetes in American black, Hispanic, and Asian/Pacific Islander postmenopausal women. Clin Chem. 2012; 58(10):1457–55.
Moncay H, Dapunt O, Moncayo R. diagnostic accuracy of basal TSH determinations based on the intravenous TRH stimulation tests: an evaluation of 2570 tests and comparison with the literature. BMC Endocr Disord. 2007; 7(5):1–5.
Zulewski H, Müller B, Exer P, Miserez AR, Staub JJ. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab. 1997; 82:771–6.
Al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab. 1997; 82:1118–25.
Barnes B. Temperature versus basal metabolism. J Am Med Assoc. 1942; 119(14):1072–4.
Friedman M, Miranda-Massari JR, Gonzalez MJ. Supraphysiological cyclic dosing of sustained release T3 in order to reset low basal body temperature. P R Health Sci J. 2006; 25(1):23–9.
Hackney AC, Feith S, Pozos R, Seale J. Effects of high altitude and cold exposure on resting thyroid hormone concentrations. Aviat Space Environ Med. 1995; 66(4):325–9.
Opstad PK, Falch D, Oktedalen O, et al. The thyroid function in young men during prolonged exercise and the effect of energy and sleep deprivation. Clin Endocrinol. 1984; 20:657–69.
Ellingsen DG, Efskind J, Haug E, et al. Effects of low mercury vapour exposure on the thyroid fucniton in Chloralkai workers. J Appl Toxicol. 2000; 20:483–9.
den Brinker M, Joosten KFM, Visser TJ, et al. Euthyroid sick syndrome in meningococcal sepsis: the impact of peripheral thyroid hormone metabolism and binding proteins. J Clin Endocrinol Metab. 2005; 90(10):5613–20.
Chopra IJ, Solomon DH, Hepner GW, et al. Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses. Ann Intern Med. 1979; 90(6):905–12.
Chopra IJ. A study of extrathyroidal conversion of thyroxine (T4) to 3,3′,5-triiodothyronine (T3) in vitro. Endocrinology. 1977; 101(2):453–63.
Sechman A, Niezgoda J, Sobocinski R. The relationship between basal metabolic rate (BMR) and concentrations of plasma thyroid hormones in fasting cockerels. Folia Biol (Krakow). 1989; 37(1–2):83–90.
Magri F, Cravello L, Fioravanti M, et al. Thyroid function in old and very old healthy subjects. J Endocrinol Invest. 2002; 25(10):60–3.
O’Brian JI, Baybee DE, Wartofsky L, et al. Altered peripheral thyroid hormone metabolism and diminished hypothalamic pituitary responsiveness with changes in dietary composition. Clin Res. 1978; 26:310A.
Friberg L, Drvota V, Bjelak AH, Eggertsen G, Ahnve S. Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction. Am J Med. 2001; 111(9):699–703.
McCormack PD. Cold stress, reverse T3 and lymphocyte function. Alaska Med. 1998; 40(3):55–62.
Scriba PC, Bauer M, Emmert D, et al. Effects of obesity, total fasting and re-alimentation on L-thyroxine (T4), 3,5,3-L-triiodothyronine (T3), 3,3,5-L-triiodothyronine (rT3), thyroxine binding globulin (TBG), transferrin, 2-haptoglobin and complement C3 in serum. Acta Endocrinol. 1979; 91:629–43.
Kvetny J. Thyroxine binding and cellular metabolism of thyroxine in mononuclear blood cells from patients with anorexia nervosa. J Endocrinol. 1983; 98(3):343–50.
Germain DL. Metabolic effect of 3,3′,5′-triiodothyronine in cultured growth hormone-producing rat pituitary tumor cells. Evidence for a unique mechanism of thyroid hormone action. J Clin Invest. 1985; 76(2):890–3.
Szymanski PT, Nauman J. Effects of thyroid hormones and reverse T3 pretreatment on the beta adrenoreceptors in the rat heart. Acta Physiol Pol. 1986; 37:131–8.
du Pont JS. Is reverse T3 a physiological nonactive competitor of the action of T3 upon the electrical properties of GH3 cells?Neuroendocrinology. 1991; 54:146–50.
Schulte C. Low T3 syndrome and nutritional status as prognostic factors in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1998; 22:1171–8.
Goichot B, Schlienger JL, Grunenberger F, et al. Thyroid hormone status and nutrient intake in the free-living elderly. Interest of reverse triiodothyronine assessment. Eur J Endocrinol. 1994; 130:244–52.
Okamoto R, Leibfritz D. Adverse effects of reverse triodothyronine on cellular metabolism as assessed by 1H and 31P NMR spectroscopy. Res Exp Med. 1997; 197:211–7.
de Jong FJ, den Heijer T, Visser TJ, et al. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin EndocrinolMetab. 2006; 91(7):2569–73.
Forestier E, Vinzio S, Sapin R, et al. Increased reverse T3 is associated with shorter survival in independently-living elderly. The Alsanut Study.Eur J Endocrinol. 2009; 160(2):207–14.
Visser TJ, Lamberts WJ, Wilson JHP, et al. Serum thyroid hormone concentrations during prolonged reduction of dietary intake. Metabolism. 1978; 27(4):405–9.
Linnoila M, Lamberg BA, Potter WZ, et al. High reverse T3 levels in manic and unipolar depressed women. Psych Res. 1982; 6:271–6.
McCormack PD, Reed HL, Thomas JR, et al. Increased in rT3 serum levels observed during extended Alaskan field operations of naval personnel. Alaska Med. 1996; 38(3):89–97.
Mariotti S, Barbesino G, Caturegli P, et al. Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab. 1993; 77(5):1130–4.
Danforth EJ, Desilets EJ, Jorton ES, et al. Reciprocal serum triiodothryronine (T3) and reverse (rT3) induced by altering the carbohydrate content of the diet. Clin Res. 1975; 23:573.
McCormack PD, Thomas J, Malik M, Staschen CM. Cold stress, reverse T3 and lymphocyte function. Alaskan Med. 1998; 40(3):55–62.
Peeters RP, Wouters PJ, van Toor H, et al. Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab. 2005; 90(8):4559–65.
Szabolcs I, Weber M, Kovacs Z, et al. The possible reason for serum 3,3′5′-(reverse T3) triiodothyronine increase in old people. Acta Med Acad Sci Hung. 1982; 39(1–2):11–17.
Silberman H, Eisenberg D, Ryan J, et al. The relation of thyroid indices in the critically ill patient to prognosis and nutritional factors. Surg Gynecol Obstet. 1988; 166(3):223–8.
Stan M, Morris JC. Thyrotropin-axis adaptation in aging and chronic disease. Endocrinol Metab Clin N Am. 2005; 34:973–92.
LoPresti JS, Eigen A, Kaptein E, et al. Alterations in 3,3′,5′-Triiodothyronine metabolism in response to propylthiouracil, dexamethasone, and thyroxine administration in man. J Clin Invest. 1989; 84:1650–6.
Palmblad J, Levi L, Burger A, et al. Effects of total energy withdrawal (fasting) on the levels of growth hormone, thyrotropin, cortisol, adrenaline, noradrenaline, T4, T3, and rT3 in healthy males. Acta Med Scand. 1977; 201:15–22.
Reinhardt W, Misch C, Jockenhovel F, et al. Triiodothyronine (T3) reflects renal graft function after renal transplantation. Clin Endocrinol. 1997; 46:563–9.
Chopra IJ, Chopra U, Smith SR, et al. Reciprocal changes in serum concentrations of 3,3′5′-triiodothyronine (reverse T3) and 3,3′5-triiodothyronine (T3) in systemic illnesses. J Clin Endocrinol Metab. 1975; 41(6):1043–9.
Spaulding SW, Chopra IJ, Swherwin RS, et al. Effect of caloric restriction and dietary compostion on serum T3 and reverse T3 in man. J Clin Endocrrinol Metab. 1976; 42(197):197–200.
Girdler SS, Pedersen CA, Light KC. Thyroid axis function during the menstrual cycle in women with premenstrual syndrome.Psychoneruoendocrinology. 1995; 20(4):395–403.
Peeters RP, Wouters PJ, Kaptein E, et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab. 2003; 88:3202–11.
Pittman JA, Tingley JO, Nickerson JF, Hill SR. Antimetabolic activity of 3,3′,5′-triiodo-DL-thyronine in man. Metabolism. 1960; 9:293–5.
Desai M, Irani AJ, Patil K, et al. The importance of reverse triiodothyroinine in hypothyroid children on replacement treatement. Arch Dis Child. 1984; 59:30–5.
Chopra IJ. A radioimmunoassay for measurement of 3,3′,5′-triiodothyronine (reverse T3). J Clin Invest. 1974; 54:583–92.
Kodding R, Hesch RD. L-3′,5′-diiodothyronine in human serum. Lancet. 1978; 312(8098):1049.
Benua RS, Kumaoka S, Leeper RD, Rawson RW. The effect of DL-3,3′,5′-triiodothyronine in Grave’s disease. J Clin Endocrinol Metab. 1959; 19:1344–6.
Chopra IJ. Study of extrathyroidal conversion of T4 to T3 in vitro: evidence that reverse T3 is a potent inhibitor of T3 production. Clin Res. 1976; 24:142A.
Gavin LA, Moeller M, Shoback D, Cavalieri RR. Reverse T3 and modulators of the calcium messenger system rapidly decrease T4-5′-deiodinase II activity in cultured mouse neuroblastoma cells. Thyroidology. 1988;(1):5–12.
Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3′,5′-triiodothyronine (reverse T3) and 3,3′5-triiodothyronine (T3). J Clin Endocrinol Metab. 1975; 41:911–20.
Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986; 63(1):1–8.
Lomenick JP, El-Sayyid M, Smith WJ. Effect of levo-thyroxine treatment on weight and body mass index in children with acquired hypothyroidism. J Pediatr. 2008; 152(1):96–100.
Acker CG, Singh AR, Flick RP, et al. A trial of thyroxine in acute renal failure. Kidney Int. 2000; 57:293–8.
Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid. 2007; 17(3):249–58.
Krotkiewski M. Thyroid hormones and treatment of obesity. Int J Obes Relat Metab Disord. 2000; 24(2):S116–9.
Lowe JC, Garrison RL, Reichman AJ, et al. Effectiveness and safety of T3 (triiodothyronine) therapy for euthyroid fibromyalgia: a double-blind placebo-controlled response-driven crossover study. Clin Bull Myofasc Ther. 1997; 2(2/3):31–58.
Lowe JC, Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. Clin Bull Myofasc Ther. 1997; 2(2/3):91–124.
Lowe JC, Garrison RL, Reichman AJ, et al. Triiodothyronine (T3) treatment of euthyroid fibromyalgia: a small-n replication of a double-blind placebo-controlled crossover study. Clin Bull Myofasc Ther. 1997; 2(4):71–88.
Yellin BA, Reichman AJ, Lowe JC. The process of Change During T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. The Metabolic Treatment of Fibromyalgia. Woodlands, TX: McDowell Publishing; 2000.
Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. J Clin Psychiatry. 1992; 53(1):16–8.
Bettendorf M, Schmidt KG, Grulich-Henn J, et al. Tri-idothyronine treatment in children after cardiac surgery: a double-blind, randomized, placebo-controlled study. Lancet. 2000; 356:529–34.
Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothryronine replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized placebo-controlled study. J Clin Endocrin Metab. 2008; 93(4):1351–8.
Meyer T, Husch M, van den Berg E, et al. Treatment of dopamine-dependent shock with triiodothyronine: preliminary results. Deutsch Med Wochenschr. 1979; 104:1711–14.
Dulchavsky SA, Hendrick SR, Dutta S. Pulmonary biophysical effects of triiodothyronine (T3) augmentation during sepsis induced hypothyroidism. J Trauma. 1993; 35:104–9.
Novitzsky D, Cooper DKC, Human PA, et al. Triiodothyronine therapy for heart donor and recepient. J Heart Transplant. 1988; 7:370–6.
Dulchavsky SA, Maitra SR, Maurer J, et al. Beneficial effects of thyroid hormone administration in metabolic and hemodynamic function in hemorrhagic shock. FASEB J. 1990; 4:A952.
Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995; 333:1522–7.
Gomberg-Maitland M. Thyroid hormone and cardiovascular disease. Am Heart J. 1998; 135:187–96.
Dulchavsky SA, Kennedy PR, Geller ER, et al. T3 preserves respiratory function in sepsis. J Trauma. 1991; 31:753–9.
Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors.Transplantation. 1987; 43:852–5.
Hamilton MA, Stevenson LW, Fonarow GC, et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol. 1998; 81:443–7.
Klemperer JD, Klein IL, Ojamaa K, et al. Triidothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg. 1996; 61:1323–9.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.